Loading
This completed study tested a DNA-repair drug with radiation after breast surgery. It does not offer new enrollment.
Registry status completed, last updated 2025-12-08. Enrollment is 31 actual. Residual non-metastatic TNBC or selected high-risk hormone-receptor-positive/HER2-negative disease after neoadjuvant chemotherapy and definitive surgery. Dose escalation studied rucaparib concurrently with radiotherapy and additional maintenance. The registry design is phase 1; completion is not evidence of adjuvant efficacy.
Shares Rucaparib, PARP, Triple-negative breast cancer (TNBC).
Shares Rucaparib, PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Triple-negative breast cancer (TNBC).
Shares PARP, Triple-negative breast cancer (TNBC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/